Melanoma

June 28, 2022

Trial Results: ECOG-ACRIN Research Round-Up – Summer 2022

Summaries of recently reported ECOG-ACRIN research results
March 24, 2022

Ongoing Trial: The BAMM2 trial (EA6191) explores adding the drug hydroxychloroquine to standard treatment for certain patients with melanoma that has progressed after immunotherapy

This study is evaluating the effect of adding hydroxychloroquine to the usual treatment for patients with advanced, BRAF-mutant melanoma
December 15, 2021

Trial Results: The DREAMseq trial provides strong evidence for a new treatment sequence for patients with BRAF-mutated advanced melanoma skin cancer

Dr. Michael Atkins, a medical oncologist who specializes in melanoma, talks about the results of the DREAMseq trial and how the information will hopefully extend life for more patients with advanced melanoma
June 10, 2020

Remembering Valerie Guild, a tireless advocate for patients with melanoma

Valerie Guild was Founder and President of the non-profit organization AIM at Melanoma, and served as a patient advocate on ECOG-ACRIN’s Melanoma Committee for over ten years.